Company intelligence / Profile preview
Chengdu Shangke Pharmaceutical
Chengdu, Sichuan, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Company is engaged in innovative drug R&D, development of high-end generics, complex formulation, radiopharmaceuticals, and advanced drug delivery technologies. Active across discovery, preclinical, and various clinical stages in a broad range of modalities.
- Modalities
- Small moleculeAntibodyAntibody-drug conjugateGene therapyCell therapyOligonucleotideRadiopharmaceuticalPeptidesSynthetic oligonucleotideNanoparticleRecombinant proteinBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Flame Biosciences (U.S.): Out-licensing deal for anti-Claudin 18.2 antibody and bispecifics using NovaTE platformBeta Pharma (Shanghai): Licensing for rezetinib mesylate (third-generation EGFR-TKI, NSCLC, China rights)Keymed Bioscience (Chengdu): Multiple deals for monoclonal antibodies for asthma, COPD, and nervous system diseases
Beyond the preview
Go deeper on Chengdu Shangke Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Shangke Pharmaceutical.